Why CAMP4?
Leadership
Investors
About Our Name
RAP Platform
RNA Actuators
Programmable Therapeutics
Publications & Presentations
Pipeline
Newsroom
Join the Adventure
Recent News
December 10, 2024
CAMP4 Appoints John Maraganore and Rachel Meyers as Strategic Advisors
Read More
Contact Us
Privacy Policy
Menu
Newsroom
Views and missives from the frontier
All
Press Releases
Perspectives
In the News
Videos
September 5, 2023
Press Releases
CAMP4 Therapeutics to Present at Upcoming Industry and Investor Conferences
July 5, 2023
Press Releases
Research from the Lab of CAMP4 Co-Founder Richard Young Shows That RNA Binding to Transcription Factors Fine-Tunes Gene Expression
July 20, 2022
Press Releases
CAMP4 Secures $100 Million Series B Financing to Accelerate Expansion of its Novel Regulatory RNA-Targeting Platform and Advance Lead Programs into the Clinic
April 19, 2022
Press Releases
CAMP4 Therapeutics Promotes Kelly Gold to Chief Financial Officer
March 14, 2022
Press Releases
CAMP4 Therapeutics Appoints Veteran Drug Developer Ann Barbier, M.D., Ph.D. as Chief Medical Officer
December 3, 2021
Press Releases
CAMP4 Presents In Vivo Data Supporting Novel Therapeutic Strategy for Dravet Syndrome at American Epilepsy Society Annual Meeting
September 27, 2021
Press Releases
CAMP4 Presents First Preclinical Data Demonstrating the Therapeutic Potential of its RNA Actuating Platform at the 17th Annual Meeting of the Oligonucleotide Therapeutics Society
July 13, 2021
Press Releases
CAMP4 Therapeutics Expands Leadership and Board of Directors
«
1
2
3
»
Media Contact:
PR@camp4tx.com
Top
